Shionogi’s planned USD 2 billion acquisition of IntraBio gives you a reason to revisit your Japan partner shortlist. Before you approach a potential partner, ask what your programme adds, which rights you can offer and who owns the decision. A credible commercial proposition makes the conversation worth having.
生存率だけでは捉えきれない神経毒性を、光学的電気生理、HD-MEA、ハイコンテントイメージング、ヒトiPSC由来神経系、共培養モデルを用いて多面的に評価。急性・遅発性神経毒性、神経炎症、機能・構造変化を捉えるin vitro神経毒性評価について解説します。
創薬初期に神経毒性リスクを捉え、候補化合物の比較やgo/no-go判断に活かすための考え方を解説。Cellectriconのin vitro神経毒性評価、急性・遅発性毒性、神経炎症、ヒトiPSC由来モデルを用いた早期リスク低減について紹介します。
I often hear that Daiichi Sankyo is only available as an ADC partner. This, however, is […]
The next three years will be a proving period for Astellas. Its new Corporate Strategic Plan […]
Important disclaimer This article is a general primer. It is intended to give cross-functional teams a […]
Japan’s ageing population is enormous. That does not automatically make Japan a good market for your […]
Japan changed important parts of its clinical development system in December 2023, when the Ministry of […]
Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has […]
Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to […]